Leiomyoma

WikiDoc Resources for Leiomyoma
Articles
Most recent articles on Leiomyoma Most cited articles on Leiomyoma Review articles on Leiomyoma Articles on Leiomyoma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Leiomyoma Images of Leiomyoma Photos of Leiomyoma Podcasts & MP3s on Leiomyoma Videos on Leiomyoma
Evidence Based Medicine
Cochrane Collaboration on Leiomyoma Bandolier on Leiomyoma TRIP on Leiomyoma
Clinical Trials
Ongoing Trials on Leiomyoma at Clinical Trials.gov Trial results on Leiomyoma Clinical Trials on Leiomyoma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Leiomyoma NICE Guidance on Leiomyoma NHS PRODIGY Guidance FDA on Leiomyoma CDC on Leiomyoma
Books
Books on Leiomyoma
News
Leiomyoma in the news Be alerted to news on Leiomyoma News trends on Leiomyoma
Commentary
Blogs on Leiomyoma
Definitions
Definitions of Leiomyoma
Patient Resources / Community
Patient resources on Leiomyoma Discussion groups on Leiomyoma Patient Handouts on Leiomyoma Directions to Hospitals Treating Leiomyoma Risk calculators and risk factors for Leiomyoma
Healthcare Provider Resources
Symptoms of Leiomyoma Causes & Risk Factors for Leiomyoma Diagnostic studies for Leiomyoma Treatment of Leiomyoma
Continuing Medical Education (CME)
CME Programs on Leiomyoma
International
Leiomyoma en Espanol Leiomyoma en Francais
Business
Leiomyoma in the Marketplace Patents on Leiomyoma
Experimental / Informatics
List of terms related to Leiomyoma

For patient information, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roukoz A. Karam, M.D.[2]; Cafer Zorkun, M.D., Ph.D. [3]; Shanshan Cen, M.D. [4]; Ammu Susheela, M.D. [5]

Synonyms and keywords: Uterine myoma; Fibroid; Fibroids; Uterine; Fibroid Tumor; Fibroid Uterus; Uterine fibromyoma; Leiomyomata

Overview

Uterine leiomyoma was first discovered by Hippocrates in 460-375 B.C and called it “uterine stone”. Uterine leiomyoma may be classified according to their location into 3 subtypes: submucosal, subserous, and intramural. The pathogenesis of leiomyoma is characterized by benign smooth muscle neoplasm. They can occur in any organ, but the most common forms occur in the uterus, small bowel and the esophagus. Chromosome aberrations such as t(12;14)(q14-q15;q23–24), del(7)(q22q32), rearrangements involving 6p21, 10q, trisomy 12, and deletions of 1p3q has been associated with the development of leiomyoma. Uterine leiomyoma must be differentiated from other diseases that cause uterine mass, such as: uterine adenomyoma, pregnancy, hematometra, uterine sarcoma, uterine carcinosarcoma, and metastasis. Leiomyoma is more commonly observed among patients aged 40 years and older. Common risk factors in the development of uterine leiomyoma include African-American race, early menarche, prenatal exposure to diethylstilbestrol, having one or more pregnancies extending beyond 20 weeks, obesity, significant consumption of beef and other reds meats, hypertension, family history, and alcohol consumption. Physical examination may be remarkable for enlarged, mobile uterus with an irregular contour on bimanual pelvic examination. The mainstay of therapy for uterine leiomyoma is oral contraceptive pills, either combination pills or progestin-only, Gonadotropin-releasing hormone analogs. Surgery is also part of mainstay therapy for uterine leiomyoma.

Historical Perspective

• Uterine leiomyoma was first discovered by Hippocrates, an ancient Greek physician, in 460-375 B.C and called it “uterine stone”.
• In the second century AD, Galen described the lesion as "scleromas".
• In 1860 and 1863, Rokitansky and Klob coined the term fibroid.
• In 1854, Virchow, a German pathologist, demonstrated that those tumors originated from the uterine smooth muscle.
• In 1809, the first laparotomy was conducted by Ephraim McDowell to treat leiomyoma in Danville, USA.

Classification

• Uterine leiomyoma may be classified according to the International Federation of Gynecology and Obstetrics (FIGO) classification system, based on their location in the uterus, into 8 subtypes:
  • Intramural myomas
    • FIGO types 3, 4, and 5
    • Located within the uterine wall
  • Submucosal myomas
    • Derived from myometrial cells below the endometrium and may protrude into the uterine cavity
    • May be subclassified according to this protrusion:
      • Type 0: pedunculated intracavitary
      • Type 1: < 50% intramural
      • Type 2: ≥ 50% itramural
  • Subserosal myomas
    • FIGO types 6 and 7
    • Derived from myometrium at the at the serous surface of the uterus
  • Cervical myomas
    • FIGO type 8
    • Usually located in the cervix

Pathophysiology

• The pathogenesis of leiomyoma is characterized by benign smooth muscle neoplasm. They can occur in any organ, but the most common forms occur in the uterus, small bowel and the esophagus.
• It is thought that leiomyoma is the result of either transformation of normal uterine muscle cells into abnormal cells through somatic mutations, or through the growth of abnormal uterine muscle cells into tumors.
• Genetic mutations involved in the pathogenesis of leiomyoma include:
  • t(12;14)(q14-q15;q23–24)
  • del(7)(q22q32)
  • Rearrangements involving 6p21, 10q, trisomy 12
  • Deletions of 1p3q
• On gross pathology, round, well circumscribed, non-encapsulated, solid white or tan nodules, and whorled are characteristic findings of leiomyoma.
• On microscopic histopathological analysis, elongated and spindle-shaped cells with a cigar-shaped nucleus are characteristic findings of leiomyoma.

• 

  Leiomyoma enucleated from a uterus. External surface on left; cut surface on right

• 

  A large, solitary leiomyoma in the uterus, distoring the endometrial cavity into a Y shape by splaying and pressing it downwards.
  (Image courtesy of Ed Uthman, MD)

Causes

• Chromosome aberrations such as t(12;14)(q14-q15;q23–24), del(7)(q22q32), rearrangements involving 6p21, 10q, trisomy 12, and deletions of 1p3q have been associated with the development of leiomyoma.

Differentiating Leiomyoma from other Diseases

Leiomyoma is a cause of abnormal uterine bleeding and can result in infertility. There are several diseases which can result in excessive uterine bleeding and the following table is a description of various causes of excessive uterine bleeding.

	Clinical Features	Physical Examination	Diagnostic Findings
Endometriosis	Dysmenorrhea Dyspareunia Infertility Common in women between 25 to 35 years	Nodules in the posterior fornix Adnexal masses Fixed retroverted uterus Lateral displacement of the cervix	Increased serum cancer antigen-125  Nodules of the recto vaginal septum and hypoechoic, vascular mass on MRI Laproscopic visualization confirms the diagnosis
Adenomyosis	Abnormal uterine bleeding Dysmenorrhea Common in women aged 40 and 50 years	Diffuse uterine enlargement always less than size corresponding to less than 12 weeks of gestation	Asymmetric thickening of the myometrium on MRI
Submucous uterine leiomyomas	Menorrhagia Pelvic pressure and pain Infertility Peak age of onset 25 to 44 years of age	Mobile uterus with an irregular contour	Transvaginal ultrasound will demonstrate the presence of myomas
Pelvic Inflammatory disease	Seen in patients with history of sexually transmitted disease History of multiple sexual partners  Common in women younger than 25 years of age	Abdominal tenderness  Acute cervical motion, uterine, and adnexal tenderness Visualization of purulent endocervical discharge	Positive Nucleic acid amplification tests for Chlamydia trachomatis and N. gonorrhoeae Gram negative diplococci on gram stain
Pelvic congestion Syndrome	Shifting lower abdominal pain Deep dyspareunia Post-coital pain Exacerbation of pain after prolonged standing	Bimanual tenderness Cervical motion tenderness	Pelvic varicosities on ultrasound with reduced blood flow

Epidemiology and Demographics

Age

• Leiomyoma commonly affects individuals between menarche and menopause.
• The incidence increases with age during reproductive years.

Race

• Leiomyoma usually affects African-American women.
  • Incidence rates are approximately threefold greater in African-American women than in white women.

Risk Factors

• Common risk factors in the development of uterine leiomyoma include:
  • African-American race
  • Early menarche
  • Prenatal exposure to diethylstilbestrol
  • Parity
    • Having one or more pregnancies extending beyond 20 weeks
  • Obesity
  • Diet
    • Significant consumption of beef and other reds meats
  • Alcohol consumption

Natural History, Complications and Prognosis

• The majority of patients with uterine leiomyoma remain asymptomatic for a long time; they are usually found incidentally on imaging or examined after patients start having symptoms.
• Studies have shown that 7 to 40% of premenopausal patients with leiomyoma may witness regression of fibroids over 6 months to 3 years.
• At menopause most fibroids will start to shrink as menstrual cycles stop and hormone levels wane.
• Common complications of uterine leiomyoma include:
  • Dysmenorrhea
  • Dyspareunia
  • Leiomyoma degeneration or torsion
  • Transcervical prolapse
  • Miscarriage

Diagnosis

Diagnostic Study of Choice

• The diagnosis of leiomyoma is based on a clinical diagnosis, which includes a pelvic exam and pelvic ultrasound finding of leiomyomas.
• A pelvic ultrasound is indicated when patients suffer from symtoms of leiomyoma.
• A biopsy is usually not needed to make the diagnosis, but should be performed if clinician is suspicious that the mass is not a fibroid.

Symptoms

• The majority of patients with leiomyoma are usually asymptomatic.
• Symptoms of uterine leiomyoma may include the following:

• Abnormal uterine bleeding
• Heavy or painful periods
• Abdominal discomfort or bloating
• Back ache
• Urinary frequency or retention
• Infertility

Physical Examination

• Common physical examination findings of leiomyoma include enlarged, mobile uterus with an irregular contour on bimanual pelvic examination

Imaging Findings

• On ultrasound imaging, uterine leiomyoma is characterized by the fibroids as focal masses with a heterogeneous texture, which usually cause shadowing of the ultrasound beam.

Other Diagnostic Studies

• Uterine leiomyoma may also be diagnosed using diagnostic hysteroscopy, magnetic resonance imaging, and hysterosalpingography.

• 
• 
• 
• 

Patient #1: MR images demonstrate large degenerating leiomyomas

• 
• 
• 
• 
• 

Patient #2: MR images demonstrate a leiomyoma prolapsing into the endometrial canal

• 
• 

Hysterosalpingogram(HSG) reveals a submucosal leiomyoma

• 
• 

Treatment

Medical Therapy

• The mainstay of therapy for uterine leiomyoma is oral contraceptive pills, either combination pills or progestin-only, Gonadotropin-releasing hormone analogs.

Surgery

• Surgery is the mainstay of therapy for uterine leiomyoma.
• Uterine artery embolization in conjunction with laparotomic myomectomy is the most common approach to the treatment of leiomyoma.
• Hysteroscopic myomectomy can also be performed for patients with uterine leiomyoma.